Cardinal Health Inc (NYSE:). shares have reached an unprecedented peak, touching an all-time high of $126.3. According to InvestingPro analysis, the stock remains undervalued despite this milestone, which underscores the company’s robust performance amidst a challenging healthcare landscape. With a market capitalization of $30.5 billion, Cardinal Health has established itself as a prominent player in the healthcare sector. Over the past year, Cardinal Health has witnessed a significant uptick in its stock value, with an impressive 19.61% increase, including a remarkable 31.87% gain in the past six months. Investors have shown growing confidence in the company’s strategic initiatives and its ability to navigate through market fluctuations, propelling the stock to new heights. The company’s GREAT Financial Health Score on InvestingPro further validates this momentum. The achievement of this all-time high serves as a testament to Cardinal Health’s enduring strength and potential for continued growth in the competitive healthcare sector. The company’s commitment to shareholder value is evidenced by its 43-year track record of consecutive dividend payments, demonstrating remarkable stability in the dynamic healthcare market.
In other recent news, Cardinal Health has raised its full-year earnings forecast for fiscal year 2025, primarily driven by strength within the Pharmaceutical (TADAWUL:) and Specialty Solutions segment. The company now expects its non-GAAP EPS to be at the higher end of the previously projected range of $7.75 to $7.90. Cardinal Health has also announced plans to acquire Integrated Oncology Network for $1.1 billion and is planning to acquire the majority equity interests in The GI Alliance Holdings, LLC, and Advanced Diabetes Supply Group. The company successfully raised $2.9 billion through a public offering of senior notes to partially finance these acquisitions.
Cardinal Health’s stock rating has been upgraded from Hold to Buy by TD Cowen, with a new price target set at $144. The upgrade is grounded in the expectation that Cardinal Health will outperform current earnings projections due to new customer acquisitions, strong utilization trends, and recent mergers and acquisitions in specialty services. Evercore ISI upgraded its rating on Cardinal Health shares from In Line to Outperform, suggesting potential for higher long-term guidance. BofA Securities also upgraded Cardinal Health stock from Neutral to Buy, adjusting the price target upward to $145, expecting an upside to EPS estimates.
Lastly, T2 Biosystems (NASDAQ:) decided to license its sepsis detection technology following a commercial agreement with Cardinal Health, aiming to improve patient outcomes, reduce mortality rates, and lower healthcare costs by enabling faster, targeted antimicrobial decisions. These are all recent developments that highlight the ongoing growth and strategic initiatives of Cardinal Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
